Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,441 stopped studies mapped to Leukemia and descendants · 87% state a reason
Over the 1,441 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02826642 | A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia | Phase 1 | withdrawn | Jul 11, 2016 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT00808080 | A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell…(AMLCTL) | Phase 1 / Phase 2 | terminated | Dec 15, 2008 | Thomas A. Lane, MD | lack of accrual | Enrollment / accrual |
| NCT02030405 | Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 2 | terminated | Jan 8, 2014 | Steven E. Coutre | Regulatory | Other (stated, no rule matched) |
| NCT02627573 | Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT | Phase 2 | terminated | Dec 11, 2015 | St. Petersburg State Pavlov Medical University | Poor recruitment | Enrollment / accrual |
| NCT03381118 | Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients | Phase 2 | terminated | Dec 21, 2017 | St. Petersburg State Pavlov Medical University | Unexpected toxicity | Safety / toxicity |
| NCT02518750 | Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or… | Phase 2 | terminated | Aug 10, 2015 | St. Jude Children's Research Hospital | Due to slow accrual | Enrollment / accrual |
| NCT00801931 | Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders | Phase 1 / Phase 2 | terminated | Dec 4, 2008 | Columbia University | Poor accrual | Enrollment / accrual |
| NCT01116232 | Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease… | Phase 2 | terminated | May 4, 2010 | Barbara Ann Karmanos Cancer Institute | Lack of funding. | Funding |
| NCT02418000 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or… | Phase 1 / Phase 2 | terminated | Apr 16, 2015 | Spirita Oncology, LLC | Insufficient efficacy in Phase 1 dose-escalation portion of study | Efficacy / futility |
| NCT01283386 | A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and… | Phase 4 | terminated | Jan 26, 2011 | Hoffmann-La Roche | not stated | Not stated |
| NCT03187691 | Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal… | Phase 2 | withdrawn | Jun 15, 2017 | Matinas BioPharma Nanotechnologies, Inc. | Protocol redundancy | Other (stated, no rule matched) |
| NCT03705858 | Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia | Phase 1 | withdrawn | Oct 15, 2018 | Joseph Jurcic | Due to difficulty in finalizing the contract | Other (stated, no rule matched) |
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | Phase 1 / Phase 2 | terminated | Apr 1, 2008 | Alexion Pharmaceuticals, Inc. | The study was terminated by the Sponsor for administrative reasons and not due to any safety… | Safety / toxicity |
| NCT01701323 | Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients… | Phase 1 | terminated | Oct 5, 2012 | Nohla Therapeutics, Inc. | not stated | Not stated |
| NCT03699384 | Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients… | Phase 1 / Phase 2 | withdrawn | Oct 9, 2018 | Memorial Sloan Kettering Cancer Center | Study sponsor discontinued support | Other (stated, no rule matched) |
| NCT00928200 | Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND… | Phase 1 | terminated | Jun 25, 2009 | Therapeutic Advances in Childhood Leukemia Consortium | Study was terminated due to lack of accrual. | Enrollment / accrual |
| NCT02989675 | SugarFACT - Sugar Requirements For African Children Trial | N/A | terminated | Dec 12, 2016 | Helena Hildenwall | not stated | Not stated |
| NCT01403246 | Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With… | Phase 1 / Phase 2 | terminated | Jul 27, 2011 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Slow patient enrollment and new molecules for chronic lymphoid leukemia, have importantly reduced… | Enrollment / accrual |
| NCT01957644 | Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients… | Phase 1 | terminated | Oct 8, 2013 | Boehringer Ingelheim | not stated | Not stated |
| NCT01849276 | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML | Phase 1 | terminated | May 8, 2013 | Northwestern University | Slow accrual | Enrollment / accrual |
| NCT02003573 | Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML) | Phase 1 | terminated | Dec 6, 2013 | Boehringer Ingelheim | not stated | Not stated |
| NCT00655395 | Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk… | Phase 1 / Phase 2 | terminated | Apr 9, 2008 | Viron Therapeutics Inc | not stated | Not stated |
| NCT02611908 | Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic… | Phase 1 | withdrawn | Nov 23, 2015 | Michael Choi | No participants enrolled | Enrollment / accrual |
| NCT02412475 | Epigenetic Reprogramming in Relapse AML | Phase 1 | terminated | Apr 9, 2015 | Michael Burke | We opened a competing study with the TACL consortium | Other (stated, no rule matched) |
| NCT02614560 | A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem… | Phase 1 / Phase 2 | terminated | Nov 25, 2015 | Seagen Inc. | not stated | Not stated |
| NCT02730195 | Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic… | Phase 2 | terminated | Apr 6, 2016 | Emory University | not stated | Not stated |
| NCT00074490 | Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and… | Phase 2 | terminated | Dec 15, 2003 | National Cancer Institute (NCI) | Premature closure due to inability to accrue to ARM IVD, cohorts 1 and 2 | Enrollment / accrual |
| NCT02683395 | A Study of PLX51107 in Advanced Malignancies | Phase 1 | terminated | Feb 17, 2016 | Plexxikon | Business Decision | Sponsor / business decision |
| NCT01479582 | Providing Access to Cord Blood Units for Transplants | Phase 2 | withdrawn | Nov 24, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02454270 | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory… | Phase 1 | terminated | May 27, 2015 | Janssen Research & Development, LLC | Recent advances in the treatment of B cell malignancies resulting in new treatments being approved… | Other (stated, no rule matched) |
| NCT03591744 | Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride,… | Phase 1 | withdrawn | Jul 19, 2018 | City of Hope Medical Center | Budgetary constraints | Funding |
| NCT02785900 | Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older…(CASCADE) | Phase 3 | terminated | May 30, 2016 | Seagen Inc. | Due to safety; specifically a higher rate of deaths, including fatal infections, in the SGN33A arm… | Safety / toxicity |
| NCT02309333 | Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute… | — | terminated | Dec 5, 2014 | Emory University | Previous principal investigators left institution | Other (stated, no rule matched) |
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications… | Phase 2 | withdrawn | Feb 19, 2018 | City of Hope Medical Center | PI Withdrawal | Other (stated, no rule matched) |
| NCT01980875 | Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to… | Phase 3 | terminated | Nov 11, 2013 | Gilead Sciences | not stated | Not stated |
| NCT01980888 | Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in… | Phase 3 | terminated | Nov 11, 2013 | Gilead Sciences | not stated | Not stated |
| NCT01203930 | A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL | Phase 2 | terminated | Sep 17, 2010 | Gilead Sciences | not stated | Not stated |
| NCT00006091 | Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia… | Phase 2 | withdrawn | Mar 16, 2004 | M.D. Anderson Cancer Center | No enrollment. | Enrollment / accrual |
| NCT00023881 | Bortezomib in Treating Patients With Chronic Myelogenous Leukemia | Phase 2 | terminated | Jan 27, 2003 | M.D. Anderson Cancer Center | Lack of efficacy | Efficacy / futility |
| NCT02538926 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin… | Phase 2 | withdrawn | Sep 2, 2015 | University of Washington | Drugs unavailable | Other (stated, no rule matched) |
| NCT02676323 | Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid… | Phase 1 | terminated | Feb 8, 2016 | St. Jude Children's Research Hospital | Slow accrual | Enrollment / accrual |
| NCT00780143 | Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With… | Phase 1 / Phase 2 | terminated | Oct 27, 2008 | PharmaMar | Poor recruitment | Enrollment / accrual |
| NCT02587871 | Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute… | Phase 2 | withdrawn | Oct 27, 2015 | University of Southern California | PI decided not to pursue study | Other (stated, no rule matched) |
| NCT03365661 | QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML | Phase 2 | withdrawn | Dec 7, 2017 | Masonic Cancer Center, University of Minnesota | Sponsor halted study. | Other (stated, no rule matched) |
| NCT00038883 | Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies | N/A | terminated | Jun 7, 2002 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00212407 | New York Blood Center National Cord Blood Program | Early Phase 1 | terminated | Sep 21, 2005 | New York Blood Center | Study NCT01656603 supersedes this study; FDA IND 6637 | Other (stated, no rule matched) |
| NCT02709083 | Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic… | Phase 2 | terminated | Mar 15, 2016 | Emory University | Original principal investigator left institution | Investigator |
| NCT00037882 | PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of… | Phase 2 | terminated | May 27, 2002 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00038415 | A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a… | Phase 1 / Phase 2 | terminated | May 31, 2002 | M.D. Anderson Cancer Center | Vaccine unavailable. | Other (stated, no rule matched) |
| NCT00038805 | Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute… | Phase 2 / Phase 3 | terminated | Jun 7, 2002 | M.D. Anderson Cancer Center | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Apr 10, 2019source: clinicaltrials